Clinical Genomics Service
The Jackson Laboratory for Genomic Medicine’s CLIA-certified molecular diagnostic facility offers a molecular diagnostic test, the JAX Cancer Treatment Profile, aimed at predicting a solid tumor’s response to therapy.
The test is based on high-throughput sequencing of 190 targeted genes selected for their known association with cancer, enabling detection of mutations at 10% allele frequency of the tumor specimen.
Genes selected for use in our cancer panel
The genes on the cancer panel include known drug targets, oncogenes and tumor suppressors, genes that are frequently mutated in cancer, and genes that JAX researchers hypothesize will be future targets for therapies.
Methods used in our clinical laboratory
The methods used in the clinical laboratory allow for the rapid addition of new genomic content, driven by a dedicated clinical curation team whose focus is to ensure that clinicians and their patients receive the most up-to-date and clinically impactful genomic data.
Sequencing data and our approach to analysis
The sequence data will be analyzed using a proprietary bioinformatics approach built specifically for tumor genome analysis in a clinical environment. JAX will provide a concise and directive clinical report to ordering physicians. This physician-centered report details clinically relevant variants associated with susceptibility or resistance to currently approved therapies, and/or associated with new drugs in clinical development (clinical trials). Evidence from the medical literature will be detailed in a list of references.
